1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Tibet Pharmaceuticals, Inc.

Tibet Pharmaceuticals, Inc.

TBET
Tibet Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
1,485.00Market Cap
2008 Y
2009 Y
2010 Y
TTM
Revenue per Share
1.34
1.98
2.74
2.37
Basic EPS, GAAP
0.51
0.79
1.11
0.75
Free Cash Flow per Basic Share
0.48
0.89
0.65
0.42
Dividend per Share
0.36
0.76
0.21
- -
Book Value per Share
0.1
0.02
0.81
1.19
Tangible Book Value per Share
0.78
0.84
1.94
3.25
Basic Weighted Avg Shares
12
12
12
14
Sales/Revenue/Turnover
16
23
32
34
Operating Margin (%)
39.1
40.92
41.14
31.7
Depreciation Expense
1
1
1
1
Net Income, GAAP
6
9
13
11
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
38.08
40.18
40.61
31.79
Working Capital
5
6
16
41
LT Debt
4
4
- -
- -
Total Equity
10
11
23
47
Return on Invested Capital (%)
- -
- -
- -
30.24
Return on Capital (%)
- -
- -
- -
77.14
Return on Common Equity (%)
- -
1,372.61
270.65
88.18

Capital Structure

FRC

•

in mil. unless spec.
Mar'11
Jun'11
Sep'11
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
62
25
16

Working Capital

FRC

•

in mil. unless spec.
Mar'11
Jun'11
Sep'11
Total Current Assets
39
43
44
Cash, Cash Equivalents & STI
25
30
26
Accounts Receivable, Net
13
12
16
Inventories
1
1
2
Total Current Liabilities
5
5
3
Payables & Accruals
5
5
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
122.85%
Free Cash Flow
- -
- -
-25.45%
Net Income, GAAP
- -
- -
42.15%
Sales/Revenue/Turnover
- -
- -
40.67%
Total Cash Common Dividend
- -
- -
-71.4%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
5
4
6
7
23
2010
7
8
9
8
32
2011
8
9
9
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
0.19
- -
- -
- -
0.79
2010
0.24
0.29
0.32
- -
1.11
2011
0.18
0.25
0.11
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
0.76
2010
- -
- -
- -
- -
0.21
2011
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Hong Yu
Full Time Employees
190
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Room 1701 Wanchai Hong Kong
IPO Date
Feb 10, 2023
Similar Companies
Goodness Growth Holdings, Inc. (GDNS.CN)
Fagron N.V. (FAGR.BR)
Siegfried Holding AG (SGFEF)
The BC Bud Corporation (BCBC.CN)
Charlotte's Web Holdings, Inc. (CWBHF)
Invion Limited (IVIXF)
Business
Tibet Pharmaceuticals, Inc. (TBET) operates as a specialty pharmaceutical company focused on the research, development, manufacture, marketing, and sale of modernized traditional Tibetan medicines. Through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), the company develops both prescription and over-the-counter products targeting human respiratory, digestive, urinary, and reproductive systems; commercialized offerings include 25 Ingredients Mandrake Pill for regulating menses, treating endometritis, pelvic inflammations, and women's anemia; 15 Ingredients Gentiana Pill for bronchitis, emphysema, asthma, and hoarseness; 28 Ingredients Pinang Pill for cold waist hip pain, pus hematuria, and testis swelling; 18 Ingredients Chebulic (Myrobalan) Frusemide Pill for kidney problems, lumbar pain, frequent urination, turbid urine, diabetes, and spermatorrhea; and Pomegranate Nichirin Pill for indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emission. Products sell principally to distributors in China, which supply hospitals, hospital pharmacies, and retail pharmacies. Founded in 2009 and headquartered in Wanchai, Hong Kong, with primary operations in Diqing and Yunnan Province, China, the company maintains a presence in the pharmaceuticals industry segment. No major partnerships, acquisitions, funding rounds, product launches, or strategic shifts report within the last 1-2 years, reflecting limited recent public disclosures amid stagnant share price activity and outdated financial reporting.